Press

Rx.Health aids systems to combat vaccine hesitancy

Rx.Health aids systems to combat vaccine hesitancy

Reluctance of people to receive safe available vaccines, known as ‘vaccine hesitancy’, was already a growing concern before the COVID-19 pandemic but it never hit us as hard until recently. As COVID-19 vaccination programs across the country transition from meeting...

Rethinking digital medicine during the Covid-19 Pandemic

Rethinking digital medicine during the Covid-19 Pandemic

The current COVID-19 crisis across the globe has posed a multitude of challenges to healthcare systems worldwide. One of most important challenges is to safely maintain continuity of care for their patients while dealing with the risk and burden of the pandemic. In...

Vaccine development

Vaccine development

No vaccines have been approved for the prevention of COVID-19. There are currently more than 169 candidates undergoing development and 26 in the clinical development stage according to WHO. An ideal vaccine against SARS-CoV-2 would be effective after one or two...

TrialEngage-AGA

TrialEngage-AGA

Rx.Health's TrialEngage™ Virtual Trial Toolkit is Selected by the American Gastroenterological Association to Speed GITrials and Create Nationwide Clinical Trial Network With our partners, we have developed a unique ecosystem to support centres for excellence in...

COVAXIN TM

COVAXIN TM

COVAXIN™,  India's indigenous  COVID-19  vaccine by  Bharat  Biotech is developed in collaboration with the  Indian  Council of  Medical  Research  (ICMR) -National  Institute of  Virology  (NIV).  The indigenous, inactivated vaccine is developed and manufactured in...

Remdesivir for treatment of severe COVID-19

Remdesivir for treatment of severe COVID-19

The broad-spectrum antiviral agent remdesivir (GS-5734; Gilead Sciences, Inc) is an inhibitor of the viral RNA-dependent, RNA polymerase with inhibitory activity against SARS-CoV and the Middle East respiratory syndrome (MERS-CoV). The US FDA issued EUA (Emergency use...

We promise we don’t send spam

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!

Subscribe To Our Newsletter

Submit your details to get access to the publication

You have Successfully Subscribed!